Comparison between glypican-3 and alpha-fetoprotein in discrimination of hepatocellular carcinoma from cirrhotic patients
Attallah, A., El-Far, M., Omran, M., Saeed, A., Elbendary, M., Attallah, K., Mari, K. (2018). Comparison between glypican-3 and alpha-fetoprotein in discrimination of hepatocellular carcinoma from cirrhotic patients. EKB Journal Management System, 4(4), 459-468. doi: 10.21608/jbaar.2018.154438
Abdelfattah M. Attallah; Mohamed Abd El-Hafez El-Far; Mohamed Mostafa Omran; Aya Mohamed Saeed; Mohamed Sayed Elbendary; Kareem Abdelfattah Attallah; Khaled Farid Mari. "Comparison between glypican-3 and alpha-fetoprotein in discrimination of hepatocellular carcinoma from cirrhotic patients". EKB Journal Management System, 4, 4, 2018, 459-468. doi: 10.21608/jbaar.2018.154438
Attallah, A., El-Far, M., Omran, M., Saeed, A., Elbendary, M., Attallah, K., Mari, K. (2018). 'Comparison between glypican-3 and alpha-fetoprotein in discrimination of hepatocellular carcinoma from cirrhotic patients', EKB Journal Management System, 4(4), pp. 459-468. doi: 10.21608/jbaar.2018.154438
Attallah, A., El-Far, M., Omran, M., Saeed, A., Elbendary, M., Attallah, K., Mari, K. Comparison between glypican-3 and alpha-fetoprotein in discrimination of hepatocellular carcinoma from cirrhotic patients. EKB Journal Management System, 2018; 4(4): 459-468. doi: 10.21608/jbaar.2018.154438

Comparison between glypican-3 and alpha-fetoprotein in discrimination of hepatocellular carcinoma from cirrhotic patients

Journal of Bioscience and Applied Research
Article 11, Volume 4, Issue 4, December 2018, Page 459-468  XML PDF (506.04 K)
Document Type: Original Article
DOI: 10.21608/jbaar.2018.154438
View on SCiNiTO View on SCiNiTO
Authors
Abdelfattah M. Attallah email 1; Mohamed Abd El-Hafez El-Far2; Mohamed Mostafa Omranorcid 3; Aya Mohamed Saeed4; Mohamed Sayed Elbendary4; Kareem Abdelfattah Attallah4; Khaled Farid Mari5
1Research & Development Department, Biotechnology Research Center, New Damietta, Egypt
2Chemistry department, Faculty of Science, Mansoura University, Mansoura, Egypt
3Chemistry department, Faculty of Science, Helwan University, Helwan, Egypt
4Research & Development Department, Biotechnology Research Center, New Damietta City, Egypt
5Tropical medicine department, Faculty of Medicine, Mansoura University, Mansoura, Egypt
Abstract
Background: Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. Liver cirrhosis progression could be a consequence of developing HCC. Although alpha-fetoprotein (AFP) is widely used as, a marker for the detection of HCC, but it has poor sensitivity. Objective: Evaluate the diagnostic power of serum AFP and Glypican-3 (GPC3) as biomarkers of the development of HCC. Subjects and Methods: A total of 182 patients, 110 patients with HCC, and 72 patients with liver cirrhosis were included. AFP and GPC3 were determined using ELISA. The diagnostic power was evaluated using Area under Roc curve (AUC). Results: levels of AFP and GPC3 in sera of HCC patients were higher than in those with liver cirrhosis (p < 0.0001). AFP had Area under curve (AUC) = 0.772 with sensitivity 39.1%, specificity 97.2%, positive predictive value (PPV) 97.7%, negative predictive value (NPV) 34.3% and efficiency 53.4% while GPC3 had AUC=0.841 yielded sensitivity 76.4%, specificity 86.1%, PPV 94.4%, NPV 64.3% and efficiency 78.8%. There was significant weak correlation (r = 0.241; P < 0.001) between AFP and GPC3. Conclusions: GPC3 is a good marker for HCC diagnosis. Therefore, GPC3 may be more useful than AFP in differentiating HCC from cirrhotic patients.
Keywords
AFP; Glypican-3; Liver cirrhosis; HCC; Blood markers; Diagnosis
Statistics
Article View: 180
PDF Download: 237